Starpharma share price charges higher on UK VivaGel BV launch

The Starpharma Holdings Limited (ASX:SPL) share price is pushing higher on Wednesday after announcing the UK launch of its VivaGel BV product…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Wednesday.

In morning trade the dendrimer products developer's shares are up 3% to $1.36.

Why is the Starpharma share price pushing higher?

Investors have been buying Starpharma's shares after it announced that its VivaGel BV product has been launched in the United Kingdom under the brand Betafem BV Gel.

VivaGel BV is a novel, non-antibiotic therapy for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV.

BV is the most common vaginal condition worldwide and twice as common as thrush. One in three women will experience BV and half of these women will have recurrent BV.

Today's news follows the first European launches of the product in June 2019, including in Germany and other countries. It is available over-the-counter in Europe, without the need to see a doctor or obtain a prescription.

Management notes that Europe represents a large commercial opportunity for VivaGel BV, with access to more than 260 million women.

Dr Jackie Fairley, Starpharma CEO, said: "We are delighted to see VivaGel BV launched in the UK. Starpharma and Mundipharma are working closely together to bring this breakthrough product to European women suffering from BV. We look forward to working with Mundipharma on further registrations and launches across the globe."

Mundipharma's CEO, Raman Singh, also spoke positively of the launch.

Singh said: "VivaGel BV is an important addition to the Betadine product portfolio, which continues to evolve to support women's everyday health and well-being around the world. Together with Starpharma we look forward to realising our joint ambition for Betafe and women's health."

The two parties are not resting on their laurels, though. The release explains that they continue to work proactively on regulatory and roll-out activities of VivaGel BV across other Mundipharma's regions.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to the trading week for investors this Friday.

Read more »

A young boy points and smiles as he eats fried chicken.
Share Gainers

3 ASX All Ords shares smashing the benchmark this week

Investors are sending these three ASX All Ords shares rocketing 18% to more than 29% this week. But why?

Read more »

watch
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why APA, Flight Centre, Reece, and Transurban shares are falling today

These shares are having a tough finish to the week. But why?

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Alliance Aviation, BHP, Boss Energy, and Orthocell shares are racing higher

These shares are ending the week on a positive note. But why?

Read more »

Mum playing with her baby boy holding him on her tummy as she lays down while smiling about the Bubs share price going up today
Broker Notes

Following two unfortunate incidents, what's Macquarie's price target on Monash IVF shares?

Is Monash IVF a buying opportunity?

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Macquarie tips 18% return for this ASX 200 stock

The broker thinks this blue chip's profits are going to rebound in FY 2026.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Broker Notes

Bell Potter names more of the best ASX 200 shares to buy in FY26

These shares are among the best to buy in the new financial year according to its analysts.

Read more »